Deliang Cao

Dr. Deliang Cao

Department of Medical Microbiology, Immunology and Cell Biology, 913 N Rutledge St., Springfield, IL 62794, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
LXLongzheng Xia
Longzheng Xia
STShiming Tan
Shiming Tan
YZYujuan Zhou
Yujuan Zhou
JLJingguan Lin
Jingguan Lin
HWHeran Wang
Heran Wang
QLQianjin Liao
Qianjin Liao
Cancer is a group of cells that malignantly grow and proliferate uncontrollably. At present, treatment modes for cancer mainly comprise surgery, chemotherapy, radiotherapy, molecularly targeted therapy, gene therapy, and immunotherapy. However, the curative effects of these treatments have been limited thus far by specific characteristics of tumors. Abnormal activation of signaling pathways is involved in tumor pathogenesis and plays critical roles in growth, progression, and relapse of cancers. Targeted therapies against effectors in oncogenic signaling have improved the outcomes of cancer patients. NFκB is an important signaling pathway involved in pathogenesis and treatment of cancers. Excessive activation of the NFκB-signaling pathway has been documented in various tumor tissues, and studies on this signaling pathway for targeted cancer therapy have become a hot topic. In this review, we update current understanding of the NFκB-signaling pathway in cancer.

22 December 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
YZYujuan Zhou
Yujuan Zhou
LXLongzheng Xia
Longzheng Xia
HWHeran Wang
Heran Wang
LOLinda Oyang
Linda Oyang
MSMin Su
Min Su
Deliang CaoDeliang Cao
Deliang Cao
Cancer stem cells in progression of colorectal cancer Cancer stem cells in progression of colorectal cancer

1 September 2019 in Cancer Letters
Verified
Journal Article
Open access
ZCZhe Cao
Zhe Cao
QLQianjin Liao
Qianjin Liao
MSMin Su
Min Su
KHKai Huang
Kai Huang
JJJunfei Jin
Junfei Jin
Deliang CaoDeliang Cao
Deliang Cao
Phosphatidylinositol 3-kinase (PI3K)/AKT pathway regulates cell growth, proliferation, survival, mobility and invasion. Mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) pathway is also an important mitogenic signaling pathway involved in various cellular progresses. AKT, also named protein kinase B (PKB), is a primary mediator of the PI3K signaling pathway; and ERK at the end of MAPK signaling is the unique substrate and downstream effector of mitogen-activated protein/extracellular signal-regulated kinase (MEK). The AKT and ERK signaling are both aberrantly activated in a wide range of human cancers and have long been targeted for cancer therapy, but the clinical benefits of these targeted therapies have been limited due to complex cross-talk. Novel strategies, such as AKT/ERK dual inhibitors, may be needed.

28 December 2015 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
ZWZhiqi Wang
Zhiqi Wang
SLSai Li
Sai Li
YCYu Cao
Yu Cao
XTXuefei Tian
Xuefei Tian
RZRong Zeng
Rong Zeng
Deliang CaoDeliang Cao
Deliang Cao
Oxidative stress has long been known as a pathogenic factor of ulcerative colitis (UC) and colitis‐associated colorectal cancer (CAC), but the effects of secondary carbonyl lesions receive less emphasis. In inflammatory conditions, reactive oxygen species (ROS), such as superoxide anion free radical (), hydrogen peroxide (H2O2), and hydroxyl radical (HO∙), are produced at high levels and accumulated to cause oxidative stress (OS). In oxidative status, accumulated ROS can cause protein dysfunction and DNA damage, leading to gene mutations and cell death. Accumulated ROS could also act as chemical messengers to activate signaling pathways, such as NF‐κB and p38 MAPK, to affect cell proliferation, differentiation, and apoptosis. More importantly, electrophilic carbonyl compounds produced by lipid peroxidation may function as secondary pathogenic factors, causing further protein and membrane lesions. This may in turn exaggerate oxidative stress, forming a vicious cycle. Electrophilic carbonyls could also cause DNA mutations and breaks, driving malignant progression of UC. The secondary lesions caused by carbonyl compounds may be exceptionally important in the case of host carbonyl defensive system deficit, such as aldo‐keto reductase 1B10 deficiency. This review article updates the current understanding of oxidative stress and carbonyl lesions in the development and progression of UC and CAC.

1 February 2008 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JMJun Ma
Jun Ma
RYRuilan Yan
Ruilan Yan
XZXuyu Zu
Xuyu Zu
JCJi-Ming Cheng
Ji-Ming Cheng
KRKrishna Rao
Krishna Rao
Deliang CaoDeliang Cao
Deliang Cao
Recent studies have demonstrated that aldo-keto reductase family 1 B10 (AKR1B10), a novel protein overexpressed in human hepatocellular carcinoma and non-small cell lung carcinoma, may facilitate cancer cell growth by detoxifying intracellular reactive carbonyls. This study presents a novel function of AKR1B10 in tumorigenic mammary epithelial cells (RAO-3), regulating fatty acid synthesis. In RAO-3 cells, Sephacryl-S 300 gel filtration and DEAE-Sepharose ion exchange chromatography demonstrated that AKR1B10 exists in two distinct forms, monomers (∼40 kDa) bound to DEAE-Sepharose column and protein complexes (∼300 kDa) remaining in flow-through. Co-immunoprecipitation with AKR1B10 antibody and protein mass spectrometry analysis identified that AKR1B10 associates with acetyl-CoA carboxylase-α (ACCA), a rate-limiting enzyme of de novo fatty acid synthesis. This association between AKR1B10 and ACCA proteins was further confirmed by co-immunoprecipitation with ACCA antibody and pulldown assays with recombinant AKR1B10 protein. Intracellular fluorescent studies showed that AKR1B10 and ACCA proteins co-localize in the cytoplasm of RAO-3 cells. More interestingly, small interfering RNA-mediated AKR1B10 knock down increased ACCA degradation through ubiquitination-proteasome pathway and resulted in >50% decrease of fatty acid synthesis in RAO-3 cells. These data suggest that AKR1B10 is a novel regulator of the biosynthesis of fatty acid, an essential component of the cell membrane, in breast cancer cells.

1 September 2009 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
CWChun Wang
Chun Wang
RYRuilan Yan
Ruilan Yan
DLDixian Luo
Dixian Luo
KWKounosuke Watabe
Kounosuke Watabe
DLDuan-Fang Liao
Duan-Fang Liao
Deliang CaoDeliang Cao
Deliang Cao
Aldo-keto reductase family 1 member B10 (AKR1B10) is primarily expressed in the normal human colon and small intestine but overexpressed in liver and lung cancer. Our previous studies have shown that AKR1B10 mediates the ubiquitin-dependent degradation of acetyl-CoA carboxylase-α. In this study, we demonstrate that AKR1B10 is critical to cell survival. In human colon carcinoma cells (HCT-8) and lung carcinoma cells (NCI-H460), small-interfering RNA-induced AKR1B10 silencing resulted in caspase-3-mediated apoptosis. In these cells, the total and subspecies of cellular lipids, particularly of phospholipids, were decreased by more than 50%, concomitant with 2–3-fold increase in reactive oxygen species, mitochondrial cytochrome c efflux, and caspase-3 cleavage. AKR1B10 silencing also increased the levels of α,β-unsaturated carbonyls, leading to the 2–3-fold increase of cellular lipid peroxides. Supplementing the HCT-8 cells with palmitic acid (80 μm), the end product of fatty acid synthesis, partially rescued the apoptosis induced by AKR1B10 silencing, whereas exposing the HCT-8 cells to epalrestat, an AKR1B10 inhibitor, led to more than 2-fold elevation of the intracellular lipid peroxides, resulting in apoptosis. These data suggest that AKR1B10 affects cell survival through modulating lipid synthesis, mitochondrial function, and oxidative status, as well as carbonyl levels, being an important cell survival protein.